Branche: Applikationssoftware, Biotechnologie, Healthcare
Kapitalbedarf (in Euro): 5.000.000
Datum des Förderbescheids: 27.12.2018
Geschäftskonzept: BrainRepair®UG has developed the first curative treatment for infantile cerebral palsy caused by brain damage using stem cells from own cord blood. This therapy for approx. 30,000 children in need every year in the EU has been granted Orphan Drug Designation by EC_EMA (https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161744). The enormous potential of our product has been shown in five children (~400 worldwide) with remarkable success and without major side effects. Our treatment of brain damage in newborn infants is ready for clinical use and will enjoy EU market exclusivity, i.e., monopoly, for 12 years upon market authorization. So far we invested 4.5m € and now need to finance the clinical trial (RCT).